Fulcrum Therapeutics (FULC)

Company Profile

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

Company profile

Ticker

FULC

Exchange

NASDAQ

Website

www.fulcrumtx.com

CEO

Robert J. Gould

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001680581

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Fulcrum Therapeutics Securities Corp. ...

IRS number

474839948

FULC stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$21.00

Low target

$17.00

High target

$27.00

Latest filings (excl ownership)

View all

8-K

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

18 Jan 23

424B5

Prospectus supplement for primary offering

18 Jan 23

424B5

Prospectus supplement for primary offering

17 Jan 23

8-K

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

17 Jan 23

8-K

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

8 Nov 22

Fulcrum Therapeutics Announces Recent Business Highlights

8 Nov 22

8-K

Departure of Directors or Certain Officers

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

16 Aug 22

Transcripts

View all

FULC

Earnings call transcript

2022 Q3

12 Nov 22

FULC

Earnings call transcript

2022 Q2

11 Aug 22

FULC

Earnings call transcript

2022 Q1

9 May 22

FULC

Earnings call transcript

2021 Q4

3 Mar 22

FULC

Earnings call transcript

2021 Q3

6 Nov 21

FULC

Earnings call transcript

2021 Q2

10 Aug 21

FULC

Earnings call transcript

2021 Q1

8 May 21

FULC

Earnings call transcript

2020 Q4

4 Mar 21

FULC

Earnings call transcript

2020 Q3

10 Nov 20

FULC

Earnings call transcript

2020 Q2

12 Aug 20

Latest ownership filings

View all

Cowen Financial Products LLC

RA CAPITAL MANAGEMENT, L.P.

Financial summary

Financial statements Chart FULC financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	92.03 mm	92.03 mm	92.03 mm	92.03 mm	92.03 mm	92.03 mm
Cash burn (monthly)	(no burn)	(no burn)	8.12 mm	9.01 mm	9.29 mm	8.27 mm
Cash used (since last report)	n/a	n/a	33.60 mm	37.30 mm	38.46 mm	34.21 mm
Cash remaining	n/a	n/a	58.43 mm	54.73 mm	53.57 mm	57.82 mm
Runway (months of cash)	n/a	n/a	7.2	6.1	5.8	7.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

FULC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	103	106	-2.8%
Opened positions	24	20	+20.0%
Closed positions	27	25	+8.0%
Increased positions	35	40	-12.5%
Reduced positions	23	22	+4.5%

13F shares	Current	Prev Q	Change
Total value	549.70 mm	597.18 mm	-8.0%
Total shares	58.95 mm	47.59 mm	+23.9%
Total puts	34.20 k	69.30 k	-50.6%
Total calls	606.10 k	900.30 k	-32.7%
Total put/call ratio	0.1	0.1	-26.7%

Largest owners	Shares	Value	Change
FMR	7.81 mm	$63.15 mm	+27.4%
Ra Capital Management	7.00 mm	$56.63 mm	NEW
RTW Investments	3.99 mm	$32.25 mm	+0.6%
Third Rock Ventures III	3.96 mm	$70.09 mm	0.0%
TRV GP Iii	3.96 mm	$32.05 mm	0.0%
Suvretta Capital Management	3.53 mm	$28.54 mm	+5.1%
BLK Blackrock	2.77 mm	$22.43 mm	+4.4%
Cowen And	2.35 mm	$19.00 mm	-1.6%
TRV GP Iv	2.34 mm	$18.96 mm	0.0%
Cowen Financial Products	2.10 mm	$27.32 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Ra Capital Management	7.00 mm	+7.00 mm	NEW
FMR	7.81 mm	+1.68 mm	+27.4%
VR Adviser	1.20 mm	+1.20 mm	NEW
Adage Capital Partners GP, L.L.C.	1.32 mm	+1.05 mm	+388.9%
Sofinnova Investments	797.26 k	+797.26 k	NEW
STT State Street	0.00	-648.67 k	EXIT
Citadel Advisors	642.13 k	+586.09 k	+1045.7%
Point72 Asset Management	1.49 mm	-494.80 k	-24.9%
Vanguard	1.96 mm	+426.43 k	+27.9%
Nuveen Asset Management	158.21 k	-242.94 k	-60.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

FULC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Jan 23	Ra Capital Management	Common Stock	Buy	Acquire P	Yes	No	13	1,923,076	25.00 mm	11,609,704
13 Jan 23	Gould Robert J	Common Stock	Sell	Dispose S	No	Yes	15	6,766	101.49 k	499,864
4 Jan 23	Ra Capital Management	Common Stock	Buy	Acquire P	Yes	No	7.7968	58,369	455.09 k	9,686,628
4 Jan 23	Ra Capital Management	Common Stock	Buy	Acquire P	Yes	No	7.0276	122,334	859.71 k	9,628,259
27 Dec 22	Ra Capital Management	Common Stock	Buy	Acquire P	Yes	No	5.9941	4,089	24.51 k	9,505,925
19 Dec 22	Ra Capital Management	Common Stock	Buy	Acquire P	Yes	No	5.8997	98,787	582.81 k	9,501,836